current sp, page-36

Correct Ramses, we are.
But not blindly as some would like you to believe.
Our ~ 70% decrease from our highs are grossly over-reactive in my opinion.
Look at others with significant drops.
QRX - FDA knock back
PBT - failed to meet end points
ACR - questions over main products safety and possibility of not meeting milestones.

As KC stated we have succeeded at all trials, we have proven technology, we have perfected patch development, we have a revolutionary pain portfolio and we have an FDA waiting for safe opioid alternatives.

So what, a need for cash or people losing patience warrants these prices? Esragate is the only justification purely for its unsettling nature, but that's done and dusted. So IMO we are grossly under-rated.

Look to why you are here. It hasn't gone away, it's just brewing.
Emotion has no place in investing, those who think emotion keeps me here are mistaken. If the tech were to fail, I'd be long gone, but OxyM results already dispels that chance. As always DYOR.